Benchmark set for growth after making good progress over half year

Benchmark, the aquaculture biotechnology company, today said it performed well in the first half and made good strategic progress across its three business areas.

Trond Williksen

Benchmark develops products and solutions which improve yield, quality and animal health. It improves the genetic make-up, health and nutrition of its customers' stock.

Benchmark has a broad portfolio of products and solutions, including salmon eggs with specialist genetic traits.

Sign up to our Business newsletter

Sign up to our Business newsletter

The group's revenue from continuing operations increased by 6% to £59.5m for the six months ended 31 March 2021.

The statement added: "Good progress was made on the company’s strategic priorities particularly towards the commercialisation of its new sea lice treatment.

In genetics, the company secured new customer wins in the emerging land-based salmon segment and is expanding its egg incubation capacity in Iceland to support growth across all production paradigms.

Trond Williksen, the CEO, commented: “Benchmark has performed well in the first half and has made good strategic progress across our three business areas. This reflects our successful restructuring, the new focus and discipline on delivering on our strategic priorities to create profitable growth.

“Our financial discipline including cost containment and strict cash management enables us to invest selectively in our core business, strengthen our position in our markets and deliver on the growth opportunities ahead."